Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345446 | 0.84 | TAAR1 (0.35) | IDO1NR3C1PKMKMT2ANR3C2 | |
| SCHEMBL15933087 | 0.79 | NOTUM (0.36) | IDO1NR3C1PKMKMT2ANOTUM | |
| SCHEMBL14991592 | 0.77 | KMT2A (0.33) | IDO1NR3C1PKMKMT2ANOTUM | |
| SCHEMBL7162663 | 0.77 | KMT2A (0.33) | IDO1NR3C1PKMKMT2ANOTUM | |
| SCHEMBL11949594 | 0.77 | PTGS1 (0.39) | NR3C1PKMKMT2ANOTUM | |
| SCHEMBL29775948 | 0.74 | NOTUM (0.46) | IDO1PKMNOTUM | |
| SCHEMBL457729 | 0.74 | NOTUM (0.46) | IDO1PKMNOTUM | |
| SCHEMBL1344537 | 0.73 | KMT2A (0.39) | NR3C1PKMKMT2ANOTUMNR3C2 | |
| SCHEMBL30848125 | 0.73 | KMT2A (0.39) | NR3C1PKMKMT2ANOTUMNR3C2 | |
| SCHEMBL6919991 | 0.70 | APLNR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | IDO1 1060/4885NR3C1 3001/4885PKM 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.